Related Experiment Video
Updated: Jul 4, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer]
Libian Deng1, Yaxian Yang2, Jian Huang3
1Department of Pathology, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China.
Abstract:
V-Raf murine sarcoma viral oncogene homolog B (BRAF) alteration is one of the most essential driver genes of non-small cell lung cancer (NSCLC). BRAF encodes serine/threonine protein kinases, and its mutations typically lead to protein compositional activation, thereby activating the mitogen-activated protein kinase kinase (MEK) signaling pathway. A promising new approach for the treatment of mutated BRAF and/or downstream MEK may provide customized treatment opportunities for BRAF driven NSCLC patients. However, combination therapy is necessary to overcome the difficulties such as short duration of benefit, poor therapeutic effect of non-V600 BRAF mutations and susceptibility to drug resistance. This article reviewed the progress in structural characteristics, related signaling pathways, mutation types of BRAF gene, and the clinical pathological relationship between BRAF mutations and NSCLC, as well as the therapy, in order to provide more evidences for clinical doctors to make treatment decisions. .
Insights
BRAF alterations drive non-small cell lung cancer (NSCLC). Combination therapies targeting BRAF and MEK offer personalized treatment but require overcoming resistance and improving outcomes for non-V600 mutations.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- V-Raf murine sarcoma viral oncogene homolog B (BRAF) mutations are key drivers in non-small cell lung cancer (NSCLC).
- BRAF mutations activate the mitogen-activated protein kinase kinase (MEK) signaling pathway, promoting cancer cell growth.
- Targeting BRAF and MEK presents personalized treatment opportunities for NSCLC patients with specific mutations.
Approach:
- This review synthesizes current knowledge on BRAF gene structure, signaling pathways, and mutation types.
- It examines the clinical and pathological correlations between BRAF mutations and NSCLC.
- The review also assesses therapeutic strategies, including combination therapies, for BRAF-driven NSCLC.
Key Points:
- BRAF mutations are prevalent in NSCLC, leading to aberrant signaling.
- Non-V600 BRAF mutations often show limited therapeutic response and rapid resistance.
- Combination therapies are crucial for sustained clinical benefit and overcoming resistance mechanisms.
Conclusions:
- Understanding BRAF's structural and signaling roles is vital for NSCLC treatment.
- Further research into BRAF mutation subtypes and resistance is needed.
- Evidence-based treatment decisions for BRAF-driven NSCLC can be improved through comprehensive reviews of therapeutic options.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:38The Ras Gene
Ras is a...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...